Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Pulmonx Corp(LUNG)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LUNG
09/28/2026: LUNG (1-star) is currently NOT-A-BUY. Pass it for now.
Pulmonx Corp is a medical technology company focused on providing minimally invasive treatments for severe emphysema, primarily through its Zephyr Endobronchial Valve system. The company maintains a leading position in this specialized niche, supported by strong clinical data and its proprietary StratX AI diagnostic platform. Its primary investment story hinges on global market penetration and increasing the standard-of-care adoption for its procedures. Investors should weigh this potential against significant execution risks, including the need for specialized physician training and potential regulatory or reimbursement hurdles. This stock may suit growth-oriented investors looking for exposure to specialized medical technology, provided they are comfortable with the inherent volatility of a non-profitable, niche device company.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an early commercial stage with significant potential for market expansion in the COPD sector. |
| Momentum investor | Mixed fit | This style is conditional on positive market sentiment and sustained volume growth. |
| Value investor | Weak fit | The company is not currently profitable, making traditional value metrics like P/E inapplicable. |
| Dividend investor | Weak fit | Pulmonx is a growth-focused medical device firm and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and regulatory risks of this sector are not suitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap medical device stocks often experience sharp price swings based on clinical or regulatory news. |
| Valuation risk | Medium / high | High growth expectations are priced into the stock, leaving little room for error in execution. |
| Competition risk (respiratory devices) | Medium | Large incumbents with significant R&D budgets could potentially develop competing therapies. |
| Business quality | Medium | The company has strong intellectual property but lacks the diversified revenue base of large-cap peers. |
| Dividend income | Low / none | Investors should not expect income generation from this asset. |
| Execution risk | High | The company must continue to successfully train physicians and gain hospital adoption to achieve its long-term goals. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -76.95% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 82.78M USD | Price to earnings Ratio - | 1Y Target Price 3.4 |
Price to earnings Ratio - | 1Y Target Price 3.4 | ||
Volume (30-day avg) 330.2K shares | Beta 0.34 | 52 Weeks Range 1.13 - 2.89 | Updated Date 09/28/2026 |
52 Weeks Range 1.13 - 2.89 | Updated Date 09/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Zephyr Valve Sales | Revenue from the sale of endobronchial valves to hospitals and medical facilities. | This is the primary way the company generates revenue. |
| StratX Services | Fees for AI-based quantitative CT scan analysis. | This supports the core product and adds a recurring software-service component. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 28.33 | Enterprise Value 86.91M | Price to Sales(TTM) 0.96 |
Enterprise Value 86.91M | Price to Sales(TTM) 0.96 | ||
Enterprise Value to Revenue 0.99 | Enterprise Value to EBITDA -5.62 | Shares Outstanding 42.24M | Shares Floating 37.61M |
Shares Outstanding 42.24M | Shares Floating 37.61M | ||
Percent Insiders 4.64 | Percent Institutions 62.81 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Pulmonx Corp
Exchange NASDAQ | Headquarters Redwood City, CA, United States | ||
IPO Launch date 2020-10-01 | CEO, President & Director Mr. Glendon E. French | ||
Sector Healthcare | Industry Medical Devices | Full time employees 296 | Website https://pulmonx.com |
Full time employees 296 | Website https://pulmonx.com | ||
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.